1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

SetPoint Turns Up The Heat On Rheumatoid Arthritis Program

 
• By Tina Tan

Having raised $30m in its latest financing round, SetPoint Medical is now focusing squarely on its rheumatoid arthritis program. The neuromodulation company, which counts Medtronic, Boston Scientific and GSK among its investors, is aiming to kick off Phase II trials before the end of the year, using a commercial-ready version of its implantable vagal nerve stimulation technology.

Neuromodulation
Setpoint Medical seeks to introduce bioelectric medicines for inflammatory diseases • Source: Shutterstock

SetPoint Medical Corp. is sharpening its focus on the rheumatoid arthritis therapy market, currently dominated by biopharmaceuticals, by channeling a good part of the $30m series D financing it recently raised into a multi-center Phase II clinical trial of its vagus nerve stimulation system.

The California company's technology is a rechargeable implant the size of a vitamin pill placed on the left side of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Neuromodulation Tech Raises Billions Despite Commercial Uncertainty

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

LinusBio Extends Hair-Based Diagnostic Beyond Autism, Expands Into Japan

 
• By Marion Webb

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

More from Device Area

Neuromodulation Tech Raises Billions Despite Commercial Uncertainty

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

LinusBio Extends Hair-Based Diagnostic Beyond Autism, Expands Into Japan

 
• By Marion Webb

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

FDA Warning Letter To Philips Targets Three Facilities For Quality Control Failures

 
• By Brian Bossetta

US FDA inspections of three Philips manufacturing sites earlier this year resulted in a September warning letter that claimed the company was not in conformity with current good manufacturing practices. Philips says it is addressing the agency’s concerns and working to enhance its quality systems.